KYMR

NASD Kymera Therapeutics, Inc.
Sep 30, 2026 · 10:07 AM ET DELAYED Market Open

$109.93 ↓ -0.58 (-0.52%) Trading Down from the previous close of $110.51, $1.79 below the day’s high of $111.72

YTD change
+41.28%
vs 20-day SMA
-5.31%
vs 200-day SMA
+18.59%

Price ranges

Previous day
$108.97 $111.92
open $110.54 close $110.51
-$0.03 (-0.03%)
Today
$109.23 $111.72
open $110.74 now $109.93
-$0.81 (-0.73%)
Past week
$108.97 $123.00
from $122.06 now $109.93
-$12.13 (-9.94%)
Past month
$108.97 $123.54
from $118.81 now $109.93
-$8.88 (-7.47%)
This year
$66.21 $130.05
from $77.81 now $109.93
+$32.12 (+41.28%)

Price & Performance

+31.03 (+39.04%) / 6M

$66.81$88.47$110.13$131.79Mar 30Jun 30Sep 29

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 15.5% away from all-time highs of $130.05
  • KYMR is up 41% since the beginning of the year
  • KYMR is up 94% over the past 12 months
  • KYMR is down 7% over the past 1 month
  • 14% of all KYMR investors are betting against KYMR

KYMR reads not so good: price sits above one of the two key moving averages, the 12-month move is +95.2%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.62
Earnings momentum +51.0% Quarterly EPS growth
Quarterly change +51.0%

Valuation

P/E ratio N/A
Enterprise value $10.2B
Beta 2.52

Balance sheet & scale

IncomeN/A
Revenue$105.0M
Cash$691.0M
Debt$78.6K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $9.1B

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $423.64 +1.32%
MRNA Moderna, Inc. $203.46 +3.13%
RVMD Revolution Medicines, Inc. $204.48 +1.36%
ROIV Roivant Sciences Ltd. $36.50 -1.30%
BNTX BioNTech SE Sponsored ADR $98.57 -0.51%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.